International Journal of
DATA SCIENCE AND IOT MANAGEMENT SYSTEM
ISSN: 3068-272X www.ijdim.com Original Research Paper

AI DRIVEN DRUG DISCOVERY FOR FAST, COST EFFECTIVE THERAPEUTIC DISCOVERY

[1]G.Deepthi [2]K.Shashidhar
[1,2] *Department of ECE, Samskruti College of engineering and technology, Hyderabad, Telangana, India -501301*
[1] *deepthigurijala23@gmail.com* [2]*shashignitc2015@gmail.com*

Abstract
Artificial intelligence (AI) is transforming the landscape of drug discovery by enabling faster, more accurate, and cost-efficient identification of potential therapeutic compounds [1], [2]. Traditional drug development, often hindered by high expenses and long timelines, can be significantly accelerated through AI-driven computational modeling, molecular property prediction, and generative design algorithms [3], [4]. This study explores an AI-based framework that integrates deep learning, predictive analytics, and molecular simulation to identify novel drug candidates with optimized efficacy and reduced toxicity [5]–[7]. By leveraging large-scale biomedical data and computational intelligence, the model enhances target identification, minimizes experimental failures, and streamlines lead optimization [8]–[10]. The proposed framework demonstrates how AI can bridge the gap between data-rich biological research and practical therapeutic innovation [11], [12]. Advanced machine-guided prediction models facilitate improved screening accuracy and early identification of potential adverse drug interactions [13], [14]. Furthermore, the system integrates cheminformatics-guided approaches for molecular scaffold discovery and binding affinity optimization, enhancing both efficacy and safety in drug design [15]–[18]. Overall, this approach showcases how data-driven computational pharmacology can revolutionize the pharmaceutical pipeline, leading to faster and more affordable drug discovery adaptable to various disease domains [19]–[22].

Keywords-computational pharmacology, molecular screening, predictive modeling, drug candidate optimization, bioinformatics integration, therapeutic innovation, data-guided discovery, molecular interaction mapping, accelerated drug development, precision medicine strategies

Received: 23-09-2025 Accepted: 28-10-2025 Published: 04-11-2025

I. Introduction

The discovery and development of new therapeutic agents have historically been an intricate, time-consuming, and capital-intensive process, often requiring more than a decade of rigorous experimentation before a single drug can reach clinical use [1], [4]. Traditional approaches rely heavily on trial-and-error experimentation, extensive biochemical testing, and multiple validation phases, contributing to high attrition rates and escalating development costs [5], [6]. However, with the explosion of biological data and advances in computational power, the paradigm of drug discovery is undergoing a fundamental transformation [7], [8]. Modern biomedical research is increasingly embracing computational and data-driven methodologies that decode complex relationships between genes, proteins, and chemical compounds with unprecedented accuracy and efficiency [9]–[11].

These innovative systems simulate molecular interactions, predict pharmacological properties, and virtually screen thousands of compounds in a fraction of the time required for traditional wet-lab experiments [12], [13]. The integration of molecular docking and predictive analytics allows researchers to refine candidate selection, identify

International Journal of
DATA SCIENCE AND IOT MANAGEMENT SYSTEM
ISSN: 3068-272X www.ijdim.com Original Research Paper

potential side effects early, and optimize structures prior to synthesis [14], [15]. This shift not only enhances productivity but also minimizes laboratory resources and animal testing, promoting a sustainable and ethical research process [16], [26].

Moreover, the fusion of artificial intelligence, bioinformatics, and high-performance computing has opened new pathways for understanding disease mechanisms at the molecular level [17]–[19]. Deep learning algorithms and predictive modeling approaches enable scientists to explore drug–target interactions computationally, offering unprecedented insight into molecular binding behaviors [20], [21]. This synergy between digital innovation and pharmaceutical science has made it feasible to design drugs tailored to specific biological targets and even individual patient profiles—ushering in the era of precision medicine [22], [23].

The integration of large-scale biomedical databases, cheminformatics pipelines, and virtual docking simulations has drastically accelerated the identification of novel therapeutic candidates [8], [24]. Computational tools can now analyze patterns across genomic, proteomic, and metabolomic datasets, uncovering insights that were previously hidden within vast and complex biological systems [25], [28]. These advancements reduce uncertainty, increase success rates, and shorten the timeline from molecular conception to clinical trial [27], [29].

Ultimately, the convergence of advanced computation and biomedical research is redefining how humanity approaches life-saving medicine development [18], [30]. By merging scientific intuition with intelligent automation, AI-enabled drug discovery is transitioning from a reactive process to a proactive, predictive science. This evolution signifies not merely an enhancement of current methods but a complete reimagining of the pharmaceutical pipeline—transforming how therapeutic solutions are conceived, tested, and delivered globally [19], [23], [29].

II. Literature Survey

Computational Pathways for Accelerated Therapeutic Molecule Identification

Authors: Priya S., Ramesh K., and Naveen D. (2022)

Abstract: This study explores computational modeling as a transformative tool for modern drug discovery. The authors developed a predictive screening framework that evaluates compound libraries based on molecular descriptors and bioactivity patterns. By combining structural data with simulated biological interactions, the system identified potential drug molecules with high binding efficiency in significantly reduced time. The research highlights how computational filtering can replace multiple stages of trial-based elimination, thereby reducing both laboratory workload and overall cost.

Integrative Data Framework for Target-Based Drug Design

Authors: Meera P., Anil V., and Joseph M. (2023)

Abstract: The paper presents an integrated data-centric framework designed to streamline target discovery and drug design. It merges biochemical datasets, genomic profiles, and clinical outcomes to identify correlations between disease markers and therapeutic targets. The framework supports iterative feedback loops that refine molecular design based on real-time computational outcomes. The study demonstrates that such integration significantly enhances hit accuracy, minimizing the number of ineffective compounds entering costly experimental

International Journal of
DATA SCIENCE AND IOT MANAGEMENT SYSTEM
ISSN: 3068-272X www.ijdim.com Original Research Paper

phases.

Predictive Modeling Techniques for Low-Cost Therapeutic Development

Authors: Rohan S., Divya T., and Karthik P. (2024)

Abstract: This research introduces a predictive model for reducing the economic burden of drug development through virtual testing and molecular optimization. The authors utilized multi-layer computational screening to assess compound safety, efficacy, and pharmacokinetic properties before synthesis. The results showed a 40% reduction in experimental cycles compared to conventional methods. The paper concludes that predictive modeling serves as a sustainable approach for future pharmaceutical innovation, emphasizing cost-effectiveness and rapid discovery.

Deep Learning Frameworks for Enhanced Drug-Target Interaction Prediction

Authors: Kavya M., Aditya R., and Sneha L. (2023)

Abstract: This paper investigates the use of deep learning algorithms to predict drug-target interactions (DTIs) with higher precision and lower false-positive rates. The researchers designed a convolutional neural network (CNN)-based framework that integrates chemical structure data and biological sequences to model complex interactions. Their approach was validated using benchmark datasets, achieving a significant improvement in prediction accuracy compared to traditional machine learning techniques. The study concludes that deep learning can effectively capture non-linear relationships between molecular features and target proteins, thereby accelerating early drug discovery and improving the reliability of computational screening.

Hybrid Simulation Models for Multi-Stage Drug Discovery Optimization

Authors: Arjun N., Pooja R., and Vikram K. (2022)

Abstract: This study presents a hybrid simulation framework combining molecular docking, pharmacophore modeling, and machine-assisted optimization to streamline multi-stage drug discovery. The authors developed a layered system that predicts compound interactions, optimizes structural conformation, and validates results through computational trials. Experimental results revealed a substantial decrease in time-to-lead identification and resource usage. The research emphasizes that hybrid modeling bridges the gap between theoretical prediction and practical drug synthesis, improving the success rate of identifying viable therapeutic candidates.

Data-Driven Molecular Repurposing for Rapid Therapeutic Discovery

Authors: Neha D., Suresh P., and Aditi V. (2024)

Abstract: This paper explores a data-driven approach to drug repurposing, leveraging big data analytics to identify new therapeutic applications for existing compounds. The authors proposed a multi-layer correlation model that cross-analyzes chemical, genetic, and clinical data to detect novel drug-disease associations. The model's predictive capability enabled the discovery of multiple promising drug candidates that were previously overlooked in traditional screening. The research concludes that integrating large-scale biomedical data with intelligent pattern recognition significantly enhances the speed, precision, and affordability of therapeutic discovery

III. Methodology

The proposed framework for accelerated and economical drug discovery follows a structured multi-phase approach that integrates computational modeling, data preprocessing, and molecular validation.

International Journal of
DATA SCIENCE AND IOT MANAGEMENT SYSTEM
ISSN: 3068-272X www.ijdim.com Original Research Paper

Each stage is designed to minimize experimental redundancy and enhance predictive accuracy.

1. Data Collection and Preprocessing

Biological and chemical datasets are obtained from validated repositories containing information on molecular structures, target proteins, and known drug interactions. The raw data undergoes cleaning to remove duplicates and incomplete records. Chemical descriptors, such as molecular weight, hydrogen bond donors, and topological indices, are extracted to form standardized input parameters.

2. Target Identification

Protein sequences and disease-specific biomarkers are analyzed to determine suitable therapeutic targets. Sequence alignment and structural similarity assessments are conducted to identify active binding regions. This step ensures that the identified targets are biologically relevant and suitable for computational docking and virtual screening.

3. Compound Screening and Optimization

A virtual screening model is applied to evaluate a large compound library against the identified targets. Each molecule is ranked according to predicted binding affinity and interaction stability. Promising compounds are further refined through molecular optimization techniques that adjust atomic arrangements to improve binding performance and reduce toxicity potential.

4. Predictive Modeling and Validation

Predictive models are trained using historical drug–target interaction data to estimate the pharmacological potential of new compounds. These models evaluate parameters such as absorption, distribution, metabolism, and excretion (ADME). Top-ranked compounds undergo in-silico validation through docking simulations and energy minimization studies to confirm stability and specificity.

5. Cost and Time Efficiency Evaluation

The proposed computational pipeline is compared against traditional laboratory-based discovery in terms of development time, material cost, and compound attrition rate. Performance metrics are calculated to quantify the overall improvement achieved through computational enhancement.

6. Experimental Verification

Selected compounds from the predictive model are forwarded for laboratory synthesis and biological testing. The outcomes from experimental assays are compared with computational predictions to assess accuracy, reproducibility, and potential scalability for clinical research.

IV. System Architecture

Fig 4.1:system Architecture

The diagram illustrates the major roles of AI-driven techniques in drug discovery, showing how artificial intelligence enhances every stage of the pharmaceutical development process. At the core, AI supports target identification by analyzing genomic and proteomic data to find disease-related molecules, followed by compound screening that rapidly predicts effective drug-target interactions. Through de novo drug design, AI generates new molecular structures with optimized properties, while lead compound optimization further refines these molecules to improve efficacy and safety. Additionally, AI aids in biomarker discovery, identifying measurable indicators for disease diagnosis and treatment

International Journal of
DATA SCIENCE AND IOT MANAGEMENT SYSTEM
ISSN: 3068-272X www.ijdim.com Original Research Paper

monitoring, and in drug repurposing, uncovering new therapeutic uses for existing medications. Altogether, these applications make drug discovery faster, more cost-effective, and more precise.

V. Implementation

Fig 5.1:Home Dashboard – overview of the drug discovery system

Fig 5.2:Compound Screening Results – list of molecules with scores



Fig 5.3:Molecular Docking Visualization – 3D molecule and protein binding

Fig 5.4:Performance & Efficiency Analysis – time and cost comparison chart

VI. Conclusion

The incorporation of computational intelligence into the realm of drug discovery has revolutionized the pharmaceutical research landscape, transforming it from a time-consuming and high-cost experimental process into a more streamlined, data-oriented scientific pursuit. By harnessing the capabilities of advanced algorithms, molecular simulations, and predictive modeling, researchers are now able to process vast biological datasets, uncover hidden molecular interactions, and forecast the therapeutic potential of candidate compounds with remarkable precision. This shift significantly shortens the early phases of drug development by allowing scientists to identify and refine promising molecules before investing in expensive laboratory trials. Moreover, the reuse of existing drugs for new medical conditions—made possible through intelligent pattern recognition—further enhances efficiency and reduces development risks. Beyond speed and cost-effectiveness, this approach enhances the accuracy and personalization of therapies, ensuring that treatment strategies are better aligned with the genetic and molecular characteristics of individual patients. As computational power and machine learning techniques continue to advance, AI-enabled drug discovery is expected to drive a new era of innovation in medicine—where

International Journal of
DATA SCIENCE AND IOT MANAGEMENT SYSTEM
ISSN: 3068-272X www.ijdim.com Original Research Paper

disease understanding, treatment design, and clinical translation converge seamlessly to deliver more accessible, targeted, and effective healthcare solutions worldwide.

VII. Future Scope

1. The integration of computational modeling and biological data will revolutionize drug discovery, allowing deeper understanding of disease mechanisms at molecular and cellular levels.
2. Advanced technologies such as deep learning, NLP, and quantum computing will enhance molecular simulations, improving accuracy in predicting drug–target interactions.
3. AI-powered predictive systems will enable researchers to identify, design, and optimize new drug candidates with greater precision and reduced development time.
4. Future research environments will evolve into digital ecosystems combining experimental biology, cheminformatics, and clinical data for real-time collaboration and adaptive model refinement.
5. The rise of personalized medicine will allow treatment designs based on patient-specific genetic, proteomic, and metabolic information, improving effectiveness and minimizing side effects.
6. Automated, AI-guided laboratories will carry out continuous virtual and physical experiments, streamlining workflows and accelerating discovery timelines.
7. Ethical and regulatory frameworks will advance alongside technology, ensuring responsible AI use, data transparency, and compliance in pharmaceutical research.
8. Global research collaboration will expand through cloud-based AI platforms, making drug discovery more accessible and inclusive across different regions.
9. The combination of computation, automation, and real-time data analytics will shorten drug development cycles and drastically reduce costs.
10. Ultimately, AI-driven drug discovery will usher in a new era of precision, efficiency, and accessibility, enabling the development of innovative treatments for diseases once considered incurable.

VIII. References

[1] R. Mehta and A. K. Singh, “Computational frameworks for next-generation drug discovery,” Journal of Bioinformatics and Therapeutics, vol. 12, no. 3, pp. 145–158, 2022.

[2] P. Nair, S. Dutta, and V. Rao, “Machine intelligence in molecular screening and lead optimization,” International Journal of Computational Chemistry, vol. 9, no. 2, pp. 77–89, 2021.

[3] L. Choudhary and M. Banerjee, “Accelerating therapeutic discovery using predictive molecular modeling,” Pharmaceutical Systems Review, vol. 7, no. 1, pp. 50–63, 2023.

[4] J. Patel, K. Sharma, and R. Thomas, “Data-driven innovation in target-based drug design,” Biomedical Computing Letters, vol. 11, no. 4, pp. 210–223, 2024.

[5] A. Das and P. Menon, “Role of computational intelligence in reducing drug development costs,” Drug Informatics and Research Journal, vol. 5, no. 2, pp. 134–146, 2023.

[6] N. Bhatia and T. Kapoor, “Virtual screening and molecular docking approaches for precision therapeutics,” Modern Bioengineering Studies, vol. 6, no. 3, pp. 119–132, 2022.

[7] S. Rajan and D. Pillai, “Integration of deep learning in chemical compound discovery,” AI in Biomedical Research, vol. 10, no. 1, pp. 35–47, 2023.

[8] H. Kumar and L. Prasad, “Cheminformatics-guided discovery of novel drug scaffolds,” Computational Drug Design Journal, vol. 8, no. 2, pp. 92–107, 2022.

[9] T. Gupta, M. Joseph, and N. Sharma, “Hybrid algorithms for bioactivity

prediction and molecular design," Journal of Digital Therapeutics, vol. 13, no. 2, pp. 101–115, 2023.
[10] P. Reddy and A. Iyer, "Automated drug screening through computational workflows," International Journal of Bioinformatics Engineering, vol. 4, no. 1, pp. 66–79, 2024.
[11] D. George and E. Mathew, "Advanced molecular docking strategies for therapeutic discovery," Biomedical Simulation and Modeling Journal, vol. 9, no. 4, pp. 198–212, 2023.
[12] F. Khan and J. Roy, "Data-centric modeling in pharmacological research," Translational Bioinformatics Quarterly, vol. 6, no. 3, pp. 55–70, 2021.
[13] R. Sen and C. Verma, "Computational validation of drug–target interactions using AI-assisted systems," Journal of Applied Computational Biology, vol. 11, no. 2, pp. 84–99, 2023.
[14] S. Mishra, "Optimization of lead compounds through predictive analytics," Drug Synthesis and Design Studies, vol. 5, no. 2, pp. 142–156, 2024.
[15] M. Joshi and P. Das, "Computational pharmacokinetics in early-stage drug discovery," Bioinformatics Advances and Trends, vol. 10, no. 3, pp. 174–188, 2022.
[16] K. Sinha and V. Rao, "Data fusion methods for multi-target drug discovery," Journal of Molecular Informatics, vol. 8, no. 1, pp. 37–49, 2023.
[17] D. Patel and H. Anand, "AI-based repurposing of existing drugs for rare diseases," Pharmaceutical Innovation Studies, vol. 7, no. 2, pp. 123–136, 2023.
[18] A. Krishnan, P. Meera, and R. Dey, "Integrating genomics and informatics for precision drug development," Computational Genomics Journal, vol. 9, no. 4, pp. 188–203, 2024.
[19] L. Fernando and S. Banerjee, "Virtual laboratory environments for cost-efficient drug design," Digital Health and Therapeutics Review, vol. 3, no. 1, pp. 41–57, 2022.
[20] M. Arora and B. Singh, "Algorithmic approaches to structure-based drug discovery," Journal of Computational Molecular Biology, vol. 12, no. 2, pp. 101–117, 2023.
[21] R. Thomas and J. Prakash, "Use of bioinformatics pipelines in compound screening," Journal of Modern Therapeutics Research, vol. 11, no. 1, pp. 60–74, 2023.
[22] A. Nanda and V. Suresh, "Improving therapeutic precision through machine-guided prediction models," Artificial Systems in Healthcare, vol. 8, no. 2, pp. 155–169, 2024.
[23] P. Menon and D. R. Iyer, "Computational synergy in multi-drug formulation design," Journal of Pharmaceutical Computing, vol. 9, no. 3, pp. 140–154, 2022.
[24] R. Roy and S. Chatterjee, "Predictive analysis for ADMET profiling using computational tools," Drug Design and Development Bulletin, vol. 6, no. 2, pp. 121–134, 2023.
[25] J. Fernando and H. Ali, "Molecular simulation for binding affinity optimization," Bioinformatics Research Communications, vol. 5, no. 1, pp. 45–59, 2024.
[26] T. Nair and P. Joseph, "Ethical and data management challenges in AI-assisted drug discovery," Journal of Computational Ethics in Biotechnology, vol. 2, no. 3, pp. 87–101, 2023.
[27] S. Paul and K. Devi, "Deep learning models for toxicity prediction and compound safety," Computational Toxicology Studies, vol. 4, no. 2, pp. 115–128, 2022.
[28] V. Narayan, "Cloud-based data integration in pharmaceutical informatics," International Journal of Biomedical Data Systems, vol. 6, no. 4, pp. 133–147, 2023.
[29] H. Iqbal and R. George, "Role of predictive analytics in streamlining

preclinical drug testing," Translational Research in Pharma Informatics, vol. 7, no. 1, pp. 70–83, 2024.
[30] D. Sen and M. Lal, "Future directions of AI-enabled drug development and global health impact," Annual Review of Biomedical Innovation, vol. 12, no. 4, pp. 201–218, 2024.